Mark H. Rapaport, MD

Department Chair, Department of Psychiatry

Languages

  • English

Academic Information

  • Departments: Psychiatry - Professor
  • Divisions: Adult Psychiatry

Board Certification

  • American Board of Psychiatry & Neurology (Psychiatry)
  • National Board of Medical Examiners

Academic Bio

Mark Hyman Rapaport, MD, Professor, joined the department January 1, 2021 as new Chairman of the Department of Psychiatry and CEO of the Huntsman Mental Health Institute (HMHI). Dr. Rapaport serves as the second William H. and Edna D. Stimson Presidential Endowed Chair, University of Utah School of Medicine.

From 2011-2020, Dr. Rapaport was Chairman of the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine and Chief of Psychiatric Services at Emory Healthcare in Atlanta, Georgia. Prior to that appointment, he was the Chairman of Psychiatry and Behavioral Neurosciences at Cedars-Sinai Medical Center and a Professor of Psychiatry at both Cedar-Sinai and the David Geffen School of Medicine at UCLA. He was the first holder of the Polier Chair while at Cedars-Sinai and also previously served as Director of the Mental Health Outpatient Clinical Research Center in the Department of Psychiatry at University of California, San Diego. He served as the first Chair of the National Institute on Drug Abuse (NIDA) Clinical Trials Network's Data Safety Monitoring Board and Chair of its Special Review Committee and also serves on NIH and NIMH Review Committees.

Dr. Rapaport has received peer-reviewed grant funding from the National Institute of Mental Health (NIMH), the National Center for Complimentary and Alternative Medicine, The Stanley Medical Research Institute, the Veterans Affairs Research Board and the National Alliance for Research on Schizophrenia and Depression (NARSAD) Foundation. His research interests focus on human psychoneuroimmunology, psychopharmacology research, clinical trial methodology, quality of life, and complementary and alternative medicine. Dr. Rapaport has trained and mentored students, physicians and researchers in the fields of psychopharmacology, outcomes research, and psychoneuroimmunology for over 30 years.

Dr. Rapaport's written over 190 articles for such peer-reviewed publications as The American Journal of Psychiatry, Biological Psychiatry, Journal of Clinical Psychiatry and Neuropsychopharmacology. He currently serves as Editor of Focus: The Journal of Lifelong Learning in Psychiatry, published by American Psychiatric Association Publishing, Inc. and the American Psychiatric Association. Dr. Rapaport is a member of the American College of Psychiatrists, American Society of Clinical Psychopharmacology, Anxiety Disorders Association of America, the Psychiatric Research Society and the Collegium International Neuropsychopharmacology (CINP) and the American College of Neuropsychopharmacology (ACNP). He is a distinguished fellow of the American Psychiatric Association and the CINP. Dr. Rapaport is board certified in Psychiatry by the American Board of Psychiatry and Neurology (1987-present).

Research Statement

I have had a number of research foci over the years, these include: human psychoneuroimmunology, psychopharmacology research, clinical trials methodology, quality of life, and complementary and alternative medicine.

Education History

Type School Degree
Postdoctoral Fellowship Clinical Neuroscience Branch, National Institute of Mental Health
Clinical Neuroscience
Guest Researcher
Fellowship National Institute of Mental Health
Clinical Neuroscience
Medical Staff Fellow
Research Fellow University of California, San Diego School of Medicine
Psychiatry
Research Fellow
Residency University of California, San Diego School of Medicine
Psychiatry
Chief Resident
Residency University of California, San Diego School of Medicine
Psychiatry
Resident
Internship University of California, Irvine/ VA Long Beach Healthcare System
Internal Medicine
Intern
Professional Medical University of California, San Diego School of Medicine
Medicine
M.D.
Graduate Training University of California, San Diego
Biology
Undergraduate Revelle College, University of California, San Diego
Biology
B.A.

Selected Publications

Journal Article

  1. Bigdeli TB, Fanous AH, Li Y, Rajeevan N, Sayward F, Genovese G, Gupta R, Radhakrishnan K, Malhotra AK, Sun N, Lu Q, Hu Y, Li B, Chen Q, Mane S, Miller P, Cheung KH, Gur RE, Greenwood TA, Braff DL, Consortium on the Genetics of Schizophrenia COGS, Achtyes ED, Buckley PF, Escamilla MA, Lehrer D, Malaspina DP, McCarroll SA, Rapaport MH, Vawter MP, Pato MT, Pato CN, Genomic Psychiatry Cohort GPC Investigators, Zhao H, Kosten TR, Brophy M, Pyarajan S, Shi Y, OLeary TJ, Gleason T, Przygodzki R, Muralidhar S, Gaziano JM, Million Veteran Program MVP, Huang GD, Concato J, Siever LJ, Aslan M, Harvey PD (2021). Genome-Wide Association Studies of Schizophrenia and Bipolar Disorder in a Diverse Cohort of US Veterans. Schizophr Bull, 47(2), 517-529.
  2. Rapaport MH, Schettler PJ, Larson ER, Dunlop BW, Rakofsky JJ, Kinkead B (2020). Six versus twelve weeks of Swedish massage therapy for generalized anxiety disorder: Preliminary findings. Complement Ther Med, 56, 102593.
  3. Lamon-Fava S, So J, Mischoulon D, Ziegler TR, Dunlop BW, Kinkead B, Schettler PJ, Nierenberg AA, Felger JC, Maddipati KR, Fava M, Rapaport MH (2020). Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation. Prostaglandins Leukot Essent Fatty Acids, 164, 102219.
  4. LaFaver K, LaFrance WC, Price ME, Rosen PB, Rapaport M (2020). Treatment of Functional Neurological Disorder: Current State, Future Directions, and a Research Agenda. CNS Spectrums, 1-23.
  5. Rommelfanger KS, Rapaport MH (2020). Setting a Research Agenda for FND. CNS Spectrums, 1-3.
  6. Bigdeli TB, Genovese G, Georgakopoulos P, Meyers JL, Peterson RE, Iyegbe CO, Medeiros H, Valderrama J, Achtyes ED, Kotov R, Stahl EA, Abbott C, Azevedo MH, Belliveau RA, Bevilacqua E, Bromet EJ, Byerley W, Carvalho CB, Chapman SB, DeLisi LE, Dumont AL, ODushlaine C, Evgrafov OV, Fochtmann LJ, Gage D, Kennedy JL, Kinkead B, Macedo A, Moran JL, Morley CP, Dewan MJ, Nemesh J, Perkins DO, Purcell SM, Rakofsky JJ, Scolnick EM, Sklar BM, Sklar P, Smoller JW, Sullivan PF, Macciardi F, Marder SR, Gur RC, Gur RE, Braff DL, Consortium on the Genetics of Schizophrenia COGS Investigators, Nicolini H, Escamilla MA, Vawter MP, Sobell JL, Malaspina D, Lehrer DS, Buckley PF, Rapaport MH, Knowles JA, Genomic Psychiatry Cohort GPC Consortium, Fanous AH, Pato MT, McCarroll SA, Pato CN (2019). Contributions of common genetic variants to risk of schizophrenia among individuals of African and Latino ancestry. Mol Psychiatry, 25(10), 2455-2467.
  7. Bremner JD, Gurel NZ, Jiao Y, Wittbrodt MT, Levantsevych OM, Huang M, Jung H, Shandhi MH, Beckwith J, Herring I, Rapaport MH, Murrah N, Driggers E, Ko Y-A, Alkhalaf ML, Soudan M, Song J, Ku BS, Shallenberger L, Hankus AN, Nye JA, Park J, Vaccarino V, Shah AJ, Inan OT, Pearce BD (2020). Transcutaneous Vagal Nerve Stimulation Blocks Stress-Induced Activation of Interleukin-6 and Interferon-γ in Posttraumatic Stress Disorder: A Double-Blind, Randomized, Sham-Controlled Trial. Brain, Behavior, & Immunity - Health, 9, https://doi.org/10.1016/j.bbih.2020.100138.
  8. Bremner JD, Gurel NZ, Wittbrodt MT, Shandhi MH, Rapaport MH, Nye JA, Pearce BD, Vaccarino V, Shah AJ, Park J, Bikson M, Inan OT (2020). Application of Noninvasive Vagal Nerve Stimulation to Stress-Related Psychiatric Disorders. Journal of Personalized Medicine, 10(3).
  9. Bremner JD, Moazzami K, Wittbrodt MT, Nye JA, Lima BB, Gillespie CF, Rapaport MH, Pearce BD, Shah AJ, Vaccarino V (2020). Diet, Stress and Mental Health. Nutrients, 12(8).
  10. Goldsmith DR, Rapaport MH (2020). Inflammation and Negative Symptoms of Schizophrenia: Implications for Reward Processing and Motivational Deficits. Front Psychiatry, 11, 46.
  11. Wittbrodt MT, Gurel NZ, Nye JA, Ladd S, Shandhi MMH, Huang M, Shah AJ, Pearce BD, Alam ZS, Rapaport MH, Murrah N, Ko YA, Haffer AA, Shallenberger LH, Vaccarino V, Inan OT, Bremner JD (2020). Non-invasive vagal nerve stimulation decreases brain activity during trauma scripts. Brain Stimul, 13(5), 1333-1348.
  12. Charney AW, Stahl EA, Green EK, Chen CY, Moran JL, Chambert K, Belliveau RA Jr, Forty L, Gordon-Smith K, Lee PH, Bromet EJ, Buckley PF, Escamilla MA, Fanous AH, Fochtmann LJ, Lehrer DS, Malaspina D, Marder SR, Morley CP, Nicolini H, Perkins DO, Rakofsky JJ, Rapaport MH, Medeiros H, Sobell JL, Backlund L, Bergen SE, Jurus A, Schalling M, Lichtenstein P, Knowles JA, Burdick KE, Jones I, Jones LA, Hultman CM, Perlis R, Purcell SM, McCarroll SA, Pato CN, Pato MT, Di Florio A, Craddock N, Landn M, Smoller JW, Ruderfer DM, Sklar P (2018). Contribution of Rare Copy Number Variants to Bipolar Disorder Risk Is Limited to Schizoaffective Cases. Biol Psychiatry, 86(2), 110-119.
  13. Waserstein G, Partin C, Cohen D, Schettler P, Kinkead B, Rapaport MH (2019). The prevalence and impact of psychiatric symptoms in an undiagnosed diseases clinical program. PLoS ONE, 14(6), e0216937.
  14. Miller BJ, Parker CB, Rapaport MH, Buckley PF, McCall WV (2017). Insomnia and suicidal ideation in nonaffective psychosis. Sleep, 42(2).
  15. Larson ER, Kinkead B, Edwards SA, Schettler PJ, Dunlop BW, Rakofsky JJ, Rapaport MH (2018). Model structure for protocol adherence utilizing a manualized therapeutic massage intervention. Journal of Complementary & Integrative Medicine, 16(2).
  16. Rakofsky J, Rapaport M (2018). Mood Disorders. Continuum (Minneap Minn), 24(3, BEHAVIORAL NEUROLOGY AND PSYCHIATRY), 804-827.
  17. Kinkead B, Schettler PJ, Larson ER, Carroll D, Sharenko M, Nettles J, Edwards SA, Miller AH, Torres MA, Dunlop BW, Rakofsky JJ, Rapaport MH (2017). Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial. Cancer, 124(3), 546-554.
  18. Fava M, Freeman MP, Flynn M, Hoeppner BB, Shelton R, Iosifescu DV, Murrough JW, Mischoulon D, Cusin C, Rapaport M, Dunlop BW, Trivedi MH, Jha M, Sanacora G, Hermes G, Papakostas GI (2017). Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). Brain Stimul, 11(1), 75-84.
  19. Rapaport MH, Schettler PJ, Larson ER, Carroll D, Sharenko M, Nettles J, Kinkead B (2018). Massage Therapy for Psychiatric Disorders. Focus (Am Psychiatr Publ), 16(1), 24-31.
  20. Dunlop BW, Gray J, Rapaport MH (2017). Transdiagnostic Clinical Global Impression Scoring for Routine Clinical Settings. Behav Sci (Basel), 7(3).
  21. Rommelfanger KS, Factor SA, LaRoche S, Rosen P, Young R, Rapaport MH (2017). Disentangling Stigma from Functional Neurological Disorders: Conference Report and Roadmap for the Future. Front Neurol, 8, 106.
  22. Rakofsky JJ, Cotes RO, McDonald WM, Schwartz AC, Rapaport MH (2016). Beyond the Psychiatric Horizon: Preparing Residents for the Twenty-First Century. Acad Psychiatry, 41(1), 125-131.
  23. Charney AW, Ruderfer DM, Stahl EA, Moran JL, Chambert K, Belliveau RA, Forty L, Gordon-Smith K, Di Florio A, Lee PH, Bromet EJ, Buckley PF, Escamilla MA, Fanous AH, Fochtmann LJ, Lehrer DS, Malaspina D, Marder SR, Morley CP, Nicolini H, Perkins DO, Rakofsky JJ, Rapaport MH, Medeiros H, Sobell JL, Green EK, Backlund L, Bergen SE, Jurus A, Schalling M, Lichtenstein P, Roussos P, Knowles JA, Jones I, Jones LA, Hultman CM, Perlis RH, Purcell SM, McCarroll SA, Pato CN, Pato MT, Craddock N, Landn M, Smoller JW, Sklar P (2017). Evidence for genetic heterogeneity between clinical subtypes of bipolar disorder. Transl Psychiatry, 7(1), e993.
  24. Griffiths CEM, Fava M, Miller AH, Russell J, Ball SG, Xu W, Acharya N, Rapaport MH (2017). Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies. Psychother Psychosom, 86(5), 260-267.
  25. Magen J, Rapaport MH (2016). Psychiatry Departments Under Constrained Funding Mechanisms or What Is a Chairperson to Do? Acad Psychiatry, 40(6), 869-873.
  26. Goldsmith DR, Rapaport MH, Miller BJ (2016). A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry, 21(12), 1696-1709.
  27. Miller BJ, Goldsmith DR, Paletta N, Wong J, Kandhal P, Black C, Rapaport MH, Buckley PF (2016). Parental type 2 diabetes in patients with non-affective psychosis. Schizophr Res, 175(1-3), 223-225.
  28. Dunlop BW, Rapaport MH (2016). When Should a Patient Be Declared Recovered From a Major Depressive Episode? J Clin Psychiatry, 77(8), e1026-8.
  29. Rapaport MH, Schettler P, Larson ER, Edwards SA, Dunlop BW, Rakofsky JJ, Kinkead B (2015). Acute Swedish Massage Monotherapy Successfully Remediates Symptoms of Generalized Anxiety Disorder: A Proof-of-Concept, Randomized Controlled Study. J Clin Psychiatry, 77(7), e883-91.
  30. Rapaport MH (2016). Lori L. Altshuler, MD 1957-2015. J Clin Psychiatry, 77(3), 333.
  31. Rapaport MH, Nierenberg AA, Schettler PJ, Kinkead B, Cardoos A, Walker R, Mischoulon D (2015). Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol Psychiatry, 21(1), 71-9.
  32. Rapaport MH (2014). Patients' preference for complementary and alternative medicine presents challenges for research. J Clin Psychiatry, 76(7), e886-7.
  33. Dunlop BW, Rapaport MH (2015). Antidepressant signal detection in the clinical trials vortex. J Clin Psychiatry, 76(5), e657-9.
  34. Miller BJ, Kandhal P, Rapaport MH, Mellor A, Buckley P (2014). Total and differential white blood cell counts, high-sensitivity C-reactive protein, and cardiovascular risk in non-affective psychoses. Brain Behav Immun, 45, 28-35.
  35. Walker ER, Berry FW 3rd, Citron T, Fitzgerald J, Rapaport MH, Stephens B, Druss BG (2014). Psychiatric workforce needs and recommendations for the community mental health system: a state needs assessment. Psychiatr Serv, 66(2), 115-7.
  36. Saah T, Garlow SJ, Rapaport MH (2014). Provide optimized antidepressant monotherapy with multiple drugs before considering antidepressant polypharmacy. Shanghai Jingshen Yixue, 26(6), 360-2.
  37. Miller BJ, Culpepper N, Rapaport MH (2013). C-reactive protein levels in schizophrenia: a review and meta-analysis. Clin Schizophr Relat Psychoses, 7(4), 223-30.
  38. Rakofsky JJ, Schettler PJ, Kinkead BL, Frank E, Judd LL, Kupfer DJ, Rush AJ, Thase ME, Yonkers KA, Rapaport MH (2012). The prevalence and severity of depressive symptoms along the spectrum of unipolar depressive disorders: a post hoc analysis. J Clin Psychiatry, 74(11), 1084-91.
  39. Garlow SJ, Kinkead B, Thase ME, Judd LL, Rush AJ, Yonkers KA, Kupfer DJ, Frank E, Schettler PJ, Rapaport MH (2013). Fluoxetine increases suicide ideation less than placebo during treatment of adults with minor depressive disorder. J Psychiatr Res, 47(9), 1199-203.
  40. Pato MT, Sobell JL, Medeiros H, Abbott C, Sklar BM, Buckley PF, Bromet EJ, Escamilla MA, Fanous AH, Lehrer DS, Macciardi F, Malaspina D, McCarroll SA, Marder SR, Moran J, Morley CP, Nicolini H, Perkins DO, Purcell SM, Rapaport MH, Sklar P, Smoller JW, Knowles JA, Genomic Psychiatry Cohort Consortium, Pato CN (2013). The genomic psychiatry cohort: partners in discovery. Am J Med Genet B Neuropsychiatr Genet, 162B(4), 306-12.
  41. Miller BJ, Culpepper N, Rapaport MH, Buckley P (2012). Prenatal inflammation and neurodevelopment in schizophrenia: a review of human studies. Prog Neuropsychopharmacol Biol Psychiatry, 42, 92-100.
  42. Ishak WW, Balayan K, Bresee C, Greenberg JM, Fakhry H, Christensen S, Rapaport MH (2012). A descriptive analysis of quality of life using patient-reported measures in major depressive disorder in a naturalistic outpatient setting. Qual Life Res, 22(3), 585-96.
  43. Glick ID, Zisook S, Rapaport MH (2012). Teaching the teacher: a report from the third annual American Society of Clinical Psychopharmacology teaching session. J Clin Psychiatry, 74(3), 262-4.
  44. Papakostas GI, Vitolo OV, Ishak WW, Rapaport MH, Zajecka JM, Kinrys G, Mischoulon D, Lipkin SH, Hails KA, Abrams J, Ward SG, Meisner A, Schoenfeld DA, Shelton RC, Winokur A, Okasha MS, Bari MA, Fava M (2012). A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder. J Clin Psychiatry, 73(12), 1541-7.
  45. Rapaport MH, Schettler P, Bresee C (2012). A preliminary study of the effects of repeated massage on hypothalamic-pituitary-adrenal and immune function in healthy individuals: a study of mechanisms of action and dosage. J Altern Complement Med, 18(8), 789-97.
  46. Kane JM, Hill LD, Kinon BJ, Potter WZ, Rapaport MH, Schooler NR (2012). New Clinical Drug Evaluation Unit (NCDEU) annual meeting: a great opportunity for early career psychiatrists. J Clin Psychiatry, 73(4), 504-5.
  47. Fan A, Berg A, Bresee C, Glassman LH, Rapaport MH (2012). Allopurinol augmentation in the outpatient treatment of bipolar mania: a pilot study. Bipolar Disord, 14(2), 206-10.
  48. Vilhauer JS, Young S, Kealoha C, Borrmann J, IsHak WW, Rapaport MH, Hartoonian N, Mirocha J (2011). Treating major depression by creating positive expectations for the future: a pilot study for the effectiveness of future-directed therapy (FDT) on symptom severity and quality of life. CNS Neurosci Ther, 18(2), 102-9.
  49. Gertsik L, Poland RE, Bresee C, Rapaport MH (2011). Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. J Clin Psychopharmacol, 32(1), 61-4.
  50. Ishak WW, Ha K, Kapitanski N, Bagot K, Fathy H, Swanson B, Vilhauer J, Balayan K, Bolotaulo NI, Rapaport MH (2011). The impact of psychotherapy, pharmacotherapy, and their combination on quality of life in depression. Harv Rev Psychiatry, 19(6), 277-89.
  51. Turner N, Macfadden W, Anand R, Khanna S, Rapaport MH, Haskins JT, Turkoz I, Alphs L (2011). Use of a relapse monitoring board: an independent assessment for determining relapse in clinical trials for bipolar disorder. Innov Clin Neurosci, 8(10), 19-24.
  52. IsHak WW, Greenberg JM, Balayan K, Kapitanski N, Jeffrey J, Fathy H, Fakhry H, Rapaport MH (2011). Quality of life: the ultimate outcome measure of interventions in major depressive disorder. Harv Rev Psychiatry, 19(5), 229-39.
  53. Bokarius A, Ha K, Poland R, Bokarius V, Rapaport MH, Ishak WW (2011). Attitude toward humor in patients experiencing depressive symptoms. Innov Clin Neurosci, 8(9), 20-3.
  54. Wisner KL, Conley RR, Taylor SF, Kosten T, Rapaport MH, Brown LS (2011). Researcher experiences with IRBs: a survey of members of the American College of Neuropsychopharmacology. IRB, 33(5), 14-20.
  55. Rapaport MH, Nierenberg AA, Howland R, Dording C, Schettler PJ, Mischoulon D (2011). The treatment of minor depression with St. John's Wort or citalopram: failure to show benefit over placebo. J Psychiatr Res, 45(7), 931-41.
  56. Yager J, Silverman JJ, Rapaport MH (2011). Adapting to decreased industry support of CME: lifelong education in an "industry-lite" world. Acad Psychiatry, 35(2), 101-5.
  57. Freeman MP, Rapaport MH (2011). Omega-3 fatty acids and depression: from cellular mechanisms to clinical care. J Clin Psychiatry, 72(2), 258-9.
  58. Rapaport MH, Schettler P, Breese C (2010). A preliminary study of the effects of a single session of Swedish massage on hypothalamic-pituitary-adrenal and immune function in normal individuals. J Altern Complement Med, 16(10), 1079-88.
  59. Nierenberg AA, Rapaport MH, Schettler PJ, Howland RH, Smith JA, Edwards D, Schneider T, Mischoulon D (2010). Deficits in psychological well-being and quality-of-life in minor depression: implications for DSM-V. CNS Neurosci Ther, 16(4), 208-16.
  60. Robinson D Jr, Aguilar D, Schoenwetter M, Dubois R, Russak S, Ramsey-Goldman R, Navarra S, Hsu B, Revicki D, Cella D, Rapaport MH, Renahan K, Ress R, Wallace D, Weisman M (2010). Impact of systemic lupus erythematosus on health, family, and work: the patient perspective. Arthritis Care Res (Hoboken), 62(2), 266-73.
  61. Rapaport MH, Bresee C (2009). Serial mitogen-stimulated cytokine production from continuously ill patients with schizophrenia. Neuropsychopharmacology, 35(2), 428-34.
  62. IsHak WW, Davis M, Jeffrey J, Balayan K, Pechnick RN, Bagot K, Rapaport MH (2009). The role of dopaminergic agents in improving quality of life in major depressive disorder. Curr Psychiatry Rep, 11(6), 503-8.
  63. Bresee C, Rapaport MH (2009). Persistently increased serum soluble interleukin-2 receptors in continuously ill patients with schizophrenia. Int J Neuropsychopharmacol, 12(6), 861-5.
  64. Rapaport MH (2009). Beyond acute treatment of depressive disorders. J Clin Psychiatry, 70(7), e21.
  65. Rapaport MH (2009). Helping patients with depression achieve wellness. J Clin Psychiatry, 70(5), e11.
  66. Marangell LB, Dennehy EB, Miyahara S, Wisniewski SR, Bauer MS, Rapaport MH, Allen MH (2008). The functional impact of subsyndromal depressive symptoms in bipolar disorder: data from STEP-BD. J Affect Disord, 114(1-3), 58-67.
  67. Rapaport MH (2009). Future drugs for the treatment of depression: the need to look beyond monoamine systems. CNS Spectrums, 14(3 Suppl 5), 14-6.
  68. Rapaport MH, Lydiard RB, Pitts CD, Schaefer D, Bartolic EI, Iyengar M, Carfagno M, Lipschitz A (2008). Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial. J Clin Psychiatry, 70(1), 46-57.
  69. Rapaport MH, Hales DJ (2009). Qualifications for recertification: an important but evolving set of standards. J Clin Psychiatry, 69(11), 1829, commentary 1829-30.
  70. Szeftel R, Hakak R, Meyer S, Naqvi S, Sulman-Smith H, Delrahim K, Rapaport M (2008). Training psychiatric residents and fellows in a telepsychiatry clinic: a supervision model. Acad Psychiatry, 32(5), 393-9.
  71. Howland RH, Schettler PJ, Rapaport MH, Mischoulon D, Schneider T, Fasiczka A, Delrahiem K, Maddux R, Lightfoot M, Nierenberg AA (2008). Clinical features and functioning of patients with minor depression. Psychother Psychosom, 77(6), 384-9.
  72. Gyulai L, Bauer MS, Marangell LB, Dennehy EB, Thase ME, Otto MW, Zhang H, Wisniewski SR, Miklowitz DJ, Rapaport MH, Baldassano CF, Sachs GS, STEP-BD Investiagtors (2008). Correlates of functioning in bipolar disorder. Psychopharmacol Bull, 41(4), 51-64.
  73. Rapaport MH, Thase ME (2007). Translating the evidence on atypical depression into clinical practice. J Clin Psychiatry, 68(4), e11.
  74. Rapaport MH (2007). Dietary restrictions and drug interactions with monoamine oxidase inhibitors: the state of the art. J Clin Psychiatry, 68 Suppl 8, 42-6.
  75. Rapaport MH, Skarky SB, Katzelnick DJ, Dewester JN, Harper JM, McCrary KE (2010). Time to response in generalized anxiety disorder in a naturalistic setting: combination therapy with alprazolam orally disintegrating tablets and serotonin reuptake inhibitors compared to serotonin reuptake inhibitors alone. Psychiatry (Edgemont), 3(12), 50-9.
  76. Rapaport MH, Gharabawi GM, Canuso CM, Mahmoud RA, Keller MB, Bossie CA, Turkoz I, Lasser RA, Loescher A, Bouhours P, Dunbar F, Nemeroff CB (2006). Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology, 31(11), 2505-13.
  77. Shelton RC, Haman KL, Rapaport MH, Kiev A, Smith WT, Hirschfeld RM, Lydiard RB, Zajecka JM, Dunner DL (2007). A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder. J Clin Psychiatry, 67(11), 1674-81.
  78. Culpepper L, Judd CR, Moller MD, Nemeroff CB, Rapaport MH, Ciraulo DA (2006). Clinicians on the front line: active management of depression and anxiety in primary care. JAAPA, Suppl, 4-21; quiz 22.
  79. Bresee CJ, Delrahim K, Maddux RE, Dolnak D, Ahmadpour O, Rapaport MH (2005). The effects of celecoxib augmentation on cytokine levels in schizophrenia. Int J Neuropsychopharmacol, 9(3), 343-8.
  80. Rowe SK, Rapaport MH (2006). Classification and treatment of sub-threshold depression. Current Opinion in Psychiatry, 19(1), 9-13.
  81. Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM, Howland R, Kling MA, Rittberg BR, Burke WJ, Rapaport MH, Zajecka J, Nierenberg AA, Husain MM, Ginsberg D, Cooke RG (2004). Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry, 58(5), 347-54.
  82. Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D (2004). Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry, 57(12), 1594-6.
  83. Rapaport MH, Clary C, Fayyad R, Endicott J (2005). Quality-of-life impairment in depressive and anxiety disorders. Am J Psychiatry, 162(6), 1171-8.
  84. Khan A, Kolts RL, Rapaport MH, Krishnan KR, Brodhead AE, Browns WA (2005). Magnitude of placebo response and drug-placebo differences across psychiatric disorders. Psychol Med, 35(5), 743-9.
  85. Akiskal HS, Mendlowicz MV, Jean-Louis G, Rapaport MH, Kelsoe JR, Gillin JC, Smith TL (2003). TEMPS-A: validation of a short version of a self-rated instrument designed to measure variations in temperament. J Affect Disord, 85(1-2), 45-52.
  86. Mendlowicz MV, Akiskal HS, Kelsoe JR, Rapaport MH, Jean-Louis G, Gillin JC (2003). Temperament in the clinical differentiation of depressed bipolar and unipolar major depressive patients. J Affect Disord, 84(2-3), 219-23.
  87. Ishak WW, Rapaport MH, Gotto JG (2004). The effectiveness of atypical antipsychotic medications in depressive disorders. Curr Psychiatry Rep, 6(6), 422-4.
  88. Haynes PL, McQuaid JR, Kelsoe J, Rapaport M, Gillin JC (2003). Affective state and EEG sleep profile in response to rapid tryptophan depletion in recently recovered nonmedicated depressed individuals. J Affect Disord, 83(2-3), 253-62.
  89. Lenert LA, Sturley AP, Rapaport MH, Chavez S, Mohr PE, Rupnow M (2003). Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res, 71(1), 155-65.
  90. Judd LL, Rapaport MH, Yonkers KA, Rush AJ, Frank E, Thase ME, Kupfer DJ, Plewes JM, Schettler PJ, Tollefson G (2004). Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder. Am J Psychiatry, 161(10), 1864-71.
  91. Rapaport MH, Bose A, Zheng H (2004). Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry, 65(1), 44-9.
  92. Maddux RE, Delrahim KK, Rapaport MH (2004). Quality of life in geriatric patients with mood and anxiety disorders. CNS Spectrums, 8(12 Suppl 3), 35-47.
  93. Caligiuri MP, Gentili V, Eberson S, Kelsoe J, Rapaport M, Gillin JC (2003). A quantitative neuromotor predictor of antidepressant non-response in patients with major depression. J Affect Disord, 77(2), 135-41.
  94. Rapaport MH, Schneider LS, Dunner DL, Davies JT, Pitts CD (2003). Efficacy of controlled-release paroxetine in the treatment of late-life depression. J Clin Psychiatry, 64(9), 1065-74.
  95. Landolt HP, Kelsoe JR, Rapaport MH, Gillin JC (2003). Rapid tryptophan depletion reverses phenelzine-induced suppression of REM sleep. J Sleep Res, 12(1), 13-8.
  96. Wang XF, Wang D, Zhu W, Delrahim KK, Dolnak D, Rapaport MH (2003). Studies characterizing 60 kda autoantibodies in subjects with schizophrenia. Biol Psychiatry, 53(5), 361-75.
  97. Evans L, Golshan S, Kelsoe J, Rapaport M, Resovsky K, Sutton L, Gillin JC (2002). Effects of rapid tryptophan depletion on sleep electroencephalogram and mood in subjects with partially remitted depression on bupropion. Neuropsychopharmacology, 27(6), 1016-26.
  98. Rapaport MH, Maddux RE (2011). Challenges in the development of clinical trials for major depressive disorder: lessons learned from trials in minor depression. Dialogues Clin Neurosci, 4(4), 402-7.
  99. Delrahim KK, Maddux R, Rapaport MH (2003). Long-term antidepressant treatment. Psychopharmacol Bull, 36(4), 26-38.
  100. Pollack MH, Rapaport MH, Fayyad R, Otto MW, Nierenberg AA, Clary CM (2002). Early improvement predicts endpoint remission status in sertraline and placebo treatments of panic disorder. J Psychiatr Res, 36(4), 229-36.
  101. Rapaport MH, Judd LL, Schettler PJ, Yonkers KA, Thase ME, Kupfer DJ, Frank E, Plewes JM, Tollefson GD, Rush AJ (2002). A descriptive analysis of minor depression. Am J Psychiatry, 159(4), 637-43.
  102. Rapaport MH, Endicott J, Clary CM (2002). Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. J Clin Psychiatry, 63(1), 59-65.
  103. Moore P, Seifritz E, Schlosser A, Greenfield D, Stahl S, Rapaport M, Kelsoe J (2001). Rapid tryptophan depletion plus a serotonin 1A agonist: competing effects on sleep in healthy men. Neuropsychopharmacology, 25(5 Suppl), S40-4.
  104. Brody BL, Gamst AC, Williams RA, Smith AR, Lau PW, Dolnak D, Rapaport MH, Kaplan RM, Brown SI (2001). Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology, 108(10), 1893-900; discussion 1900-1.
  105. Rapaport MH, Wolkow R, Rubin A, Hackett E, Pollack M, Ota KY (2001). Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand, 104(4), 289-98.
  106. Gillin JC, Smith-Vaniz A, Schnierow B, Rapaport MH, Kelsoe J, Raimo E, Marler MR, Goyette LM, Stein MB, Zisook S (2002). An open-label, 12-week clinical and sleep EEG study of nefazodone in chronic combat-related posttraumatic stress disorder. J Clin Psychiatry, 62(10), 789-96.
  107. Rapaport MH, Barrett C (2001). Panic disorder. Curr Psychiatry Rep, 3(4), 295-301.
  108. Rapaport MH, Manji HK (2001). The effects of lithium on ex vivo cytokine production. Biol Psychiatry, 50(3), 217-24.
  109. Patten CA, Gillin JC, Golshan S, Wolter TD, Rapaport M, Kelsoe J (2001). Relationship of mood disturbance to cigarette smoking status among 252 patients with a current mood disorder. J Clin Psychiatry, 62(5), 319-24.
  110. Rapaport MH, Delrahim KK (2005). An abbreviated review of immune abnormalities in schizophrenia. CNS Spectrums, 6(5), 392-7.
  111. Thorsteinsson HS, Gillin JC, Patten CA, Golshan S, Sutton LD, Drummond S, Clark CP, Kelsoe J, Rapaport M (2001). The effects of transdermal nicotine therapy for smoking cessation on depressive symptoms in patients with major depression. Neuropsychopharmacology, 24(4), 350-8.
  112. Gladsjo JA, Rapaport MH, McKinney R, Auerbach M, Hahn T, Rabin A, Oliver T, Haze A, Judd LL (2001). Absence of neuropsychologic deficits in patients receiving long-term treatment with alprazolam-XR for panic disorder. J Clin Psychopharmacol, 21(2), 131-8.
  113. Landolt HP, Raimo EB, Schnierow BJ, Kelsoe JR, Rapaport MH, Gillin JC (2001). Sleep and sleep electroencephalogram in depressed patients treated with phenelzine. Arch Gen Psychiatry, 58(3), 268-76.
  114. Rapaport MH, Pollack MH, Clary CM, Mardekian J, Wolkow R (2001). Panic disorder and response to sertraline: the effect of previous treatment with benzodiazepines. J Clin Psychopharmacol, 21(1), 104-7.
  115. Kelsoe JR, Spence MA, Loetscher E, Foguet M, Sadovnick AD, Remick RA, Flodman P, Khristich J, Mroczkowski-Parker Z, Brown JL, Masser D, Ungerleider S, Rapaport MH, Wishart WL, Luebbert H (2001). A genome survey indicates a possible susceptibility locus for bipolar disorder on chromosome 22. Proc Natl Acad Sci U S A, 98(2), 585-90.
  116. Paulus MP, Rapaport MH, Braff DL (2001). Trait contributions of complex dysregulated behavioral organization in schizophrenic patients. Biol Psychiatry, 49(1), 71-7.
  117. Rapaport MH (2001). Prevalence, recognition, and treatment of comorbid depression and anxiety. J Clin Psychiatry, 62 Suppl 24, 6-10.
  118. Moore P, Landolt HP, Seifritz E, Clark C, Bhatti T, Kelsoe J, Rapaport M, Gillin JC (2000). Clinical and physiological consequences of rapid tryptophan depletion. Neuropsychopharmacology, 23(6), 601-22.
  119. Pollack MH, Rapaport MH, Clary CM, Mardekian J, Wolkow R (2001). Sertraline treatment of panic disorder: response in patients at risk for poor outcome. J Clin Psychiatry, 61(12), 922-7.
  120. Kornberg JR, Brown JL, Sadovnick AD, Remick RA, Keck PE Jr, McElroy SL, Rapaport MH, Thompson PM, Kaul JB, Vrabel CM, Schommer SC, Wilson T, Pizzuco D, Jameson S, Schibuk L, Kelsoe JR (2000). Evaluating the parent-of-origin effect in bipolar affective disorder. Is a more penetrant subtype transmitted paternally? J Affect Disord, 59(3), 183-92.
  121. Clark C, Dupont R, Golshan S, Gillin JC, Rapaport MH, Kelsoe JR (2000). Preliminary evidence of an association between increased REM density and poor antidepressant response to partial sleep deprivation. J Affect Disord, 59(1), 77-83.
  122. Jean-Louis G, Mendlowicz MV, Gillin JC, Rapaport MH, Kelsoe JR, Zizi F, Landolt H, von Gizycki H (2000). Sleep estimation from wrist activity in patients with major depression. Physiol Behav, 70(1-2), 49-53.
  123. Rapaport MH, Pollack M, Wolkow R, Mardekian J, Clary C (2000). Is placebo response the same as drug response in panic disorder? Am J Psychiatry, 157(6), 1014-6.
  124. Mendlowicz MV, Jean-Louis G, Gillin JC, Akiskal HS, Furlanetto LM, Rapaport MH, Kelsoe JR (2000). Sociodemographic predictors of temperament and character. J Psychiatr Res, 34(3), 221-6.
  125. Rubin HC, Rapaport MH, Levine B, Gladsjo JK, Rabin A, Auerbach M, Judd LL, Kaplan R (2000). Quality of well being in panic disorder: the assessment of psychiatric and general disability. J Affect Disord, 57(1-3), 217-21.
  126. Saito T, Papolos DF, Chernak D, Rapaport MH, Kelsoe JR, Lachman HM (1999). Analysis of GNAZ gene polymorphism in bipolar affective disorder. Am J Med Genet, 88(4), 324-8.
  127. Rapaport MH, Guylai L, Whybrow P (1999). Immune parameters in rapid cycling bipolar patients before and after lithium treatment. J Psychiatr Res, 33(4), 335-40.
  128. Mendlowicz MV, Jean-Louis G, Gekker M, Rapaport MH (1999). Neonaticide in the city of Rio de Janeiro: forensic and psycholegal perspectives. J Forensic Sci, 44(4), 741-5.
  129. Mendlowicz MV, Rapaport MH, Thompson P, Kelsoe JR, Golshan S, Judd LL, Gillin JC (1998). A comparison of descriptive characteristics of male outpatients and inpatients with affective disorders. Int Clin Psychopharmacol, 13(6), 245-52.
  130. Seifritz E, Gillin JC, Rapaport MH, Kelsoe JR, Bhatti T, Stahl SM (1998). Sleep electroencephalographic response to muscarinic and serotonin1A receptor probes in patients with major depression and in normal controls. Biol Psychiatry, 44(1), 21-33.
  131. Moore P, Gillin C, Bhatti T, DeModena A, Seifritz E, Clark C, Stahl S, Rapaport M, Kelsoe J (1998). Rapid tryptophan depletion, sleep electroencephalogram, and mood in men with remitted depression on serotonin reuptake inhibitors. Arch Gen Psychiatry, 55(6), 534-9.
  132. Gladsjo JA, Rapaport MH, McKinney R, Lucas JA, Rabin A, Oliver T, Davis J, Auerbach M, Judd LL (1998). A neuropsychological study of panic disorder: negative findings. J Affect Disord, 49(2), 123-31.
  133. Mendlowicz MV, Rapaport MH, Mecler K, Golshan S, Moraes TM (1998). A case-control study on the socio-demographic characteristics of 53 neonaticidal mothers. Int J Law Psychiatry, 21(2), 209-19.
  134. Rapaport MH (1998). Circulating lymphocyte phenotypic surface markers in anxiety disorder patients and normal volunteers. Biol Psychiatry, 43(6), 458-63.
  135. Rapaport MH, Judd LL (1998). Minor depressive disorder and subsyndromal depressive symptoms: functional impairment and response to treatment. J Affect Disord, 48(2-3), 227-32.
  136. Bhatti T, Gillin JC, Seifritz E, Moore P, Clark C, Golshan S, Stahl S, Rapaport M, Kelsoe J (1998). Effects of a tryptophan-free amino acid drink challenge on normal human sleep electroencephalogram and mood. Biol Psychiatry, 43(1), 52-9.
  137. Rapaport MH, Davidson JR (1998). The efficacy of new pharmacological treatments for panic disorder: evaluating the trials. Psychopharmacol Bull, 34(2), 167-8.
  138. Rapaport MH, Wolkow RM, Clary CM (1998). Methodologies and outcomes from the sertraline multicenter flexible-dose trials. Psychopharmacol Bull, 34(2), 183-9.
  139. Noyes R Jr, Moroz G, Davidson JR, Liebowitz MR, Davidson A, Siegel J, Bell J, Cain JW, Curlik SM, Kent TA, Lydiard RB, Mallinger AG, Pollack MH, Rapaport M, Rasmussen SA, Hedges D, Schweizer E, Uhlenhuth EH (1997). Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol, 17(4), 247-54.
  140. Rapaport MH, Caligiuri MP, Lohr JB (1997). An association between increased serum-soluble interleukin-2 receptors and a disturbance in muscle force in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry, 21(5), 817-27.
  141. Rapaport MH, McAllister CG, Pickar D, Tamarkin L, Kirch DG, Paul SM (1997). CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. Schizophr Res, 25(2), 123-9.
  142. Gillin JC, Rapaport M, Erman MK, Winokur A, Albala BJ (1997). A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial. J Clin Psychiatry, 58(5), 185-92.
  143. Lachman HM, Kelsoe JR, Remick RA, Sadovnick AD, Rapaport MH, Lin M, Pazur BA, Roe AM, Saito T, Papolos DF (1997). Linkage studies suggest a possible locus for bipolar disorder near the velo-cardio-facial syndrome region on chromosome 22. Am J Med Genet, 74(2), 121-8.
  144. Rapaport MH, Cantor JJ (1997). Panic disorder in a managed care environment. J Clin Psychiatry, 58 Suppl 2, 51-5; discussion 55-6.
  145. Kelsoe JR, Sadovnick AD, Kristbjarnarson H, Bergesch P, Mroczkowski-Parker Z, Drennan M, Rapaport MH, Flodman P, Spence MA, Remick RA (1996). Possible locus for bipolar disorder near the dopamine transporter on chromosome 5. Am J Med Genet, 67(6), 533-40.
  146. Judd LL, Paulus MP, Wells KB, Rapaport MH (1996). Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population. Am J Psychiatry, 153(11), 1411-7.
  147. Rapaport M, Coccaro E, Sheline Y, Perse T, Holland P, Fabre L, Bradford D (1996). A comparison of fluvoxamine and fluoxetine in the treatment of major depression. J Clin Psychopharmacol, 16(5), 373-8.
  148. Gillin JC, Sohn JW, Stahl SM, Lardon M, Kelsoe J, Rapaport M, Ruiz C, Golshan S (1996). Ipsapirone, a 5-HT1A agonist, suppresses REM sleep equally in unmedicated depressed patients and normal controls. Neuropsychopharmacology, 15(2), 109-15.
  149. Rapaport MH, Bazzetta J, McAdams LA, Patterson T, Jeste DV (2012). Validation of the Scale of Functioning in Older Outpatients With Schizophrenia. Am J Geriatr Psychiatry, 4(3), 218-228.
  150. Rapaport MH, Zisook S, Frevert T, Seymour S, Kelsoe JR, Judd LL (1996). A comparison of descriptive variables for clinical patients and symptomatic volunteers with depressive disorders. J Clin Psychopharmacol, 16(3), 242-6.
  151. Kelsoe JR, Remick RA, Sadovnick AD, Kristbjarnarson H, Flodman P, Spence MA, Morison M, Mroczkowski-Parker Z, Bergesch P, Rapaport MH, Mirow AL, Blakely RD, Helgason T, Egeland JA (1996). Genetic linkage study of bipolar disorder and the serotonin transporter. Am J Med Genet, 67(2), 215-7.
  152. Rapaport MH, Frevert T, Babior S, Seymour S, Zisook S, Kelsoe J, Judd LL (1996). Comparison of descriptive variables for symptomatic volunteers and clinical patients with anxiety disorders. Anxiety, 2(3), 117-22.
  153. Gillin JC, Lauriello J, Kelsoe JR, Rapaport M, Golshan S, Kenny WM, Sutton L (1995). No antidepressant effect of biperiden compared with placebo in depression: a double-blind 6-week clinical trial. Psychiatry Res, 58(2), 99-105.
  154. Rapaport MH, Thompson PM, Kelsoe JR Jr, Golshan S, Judd LL, Gillin JC (1995). Gender differences in outpatient research subjects with affective disorders: a comparison of descriptive variables. J Clin Psychiatry, 56(2), 67-72.
  155. Rapaport MH, Frevert T, Babior S, Zisook S, Judd LL (1995). A comparison of demographic variables, symptom profiles, and measurements of functioning in symptomatic volunteers and an outpatient clinical population. Psychopharmacol Bull, 31(1), 111-4.
  156. Rapaport MH, Paniccia G, Judd LL (1995). A review of social phobia. Psychopharmacol Bull, 31(1), 125-9.
  157. Rapaport MH (1994). Immune parameters in euthymic bipolar patients and normal volunteers. J Affect Disord, 32(3), 149-56.
  158. Rapaport MH, Lohr JB (1994). Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatr Scand, 90(5), 311-5.
  159. Rapaport MH, Suminski M (1994). National Depression Screening Day: the San Diego experience. Hosp Community Psychiatry, 45(10), 1042-3.
  160. Rapaport MH, Schmidt ME, Risinger R, Manji H (1994). The effects of prolonged lithium exposure on the immune system of normal control subjects: serial serum soluble interleukin-2 receptor and antithyroid antibody measurements. Biol Psychiatry, 35(10), 761-6.
  161. Rapaport MH, McAllister CG, Kim YS, Han JH, Pickar D, Nelson DL, Kirch DG, Paul SM (1994). Increased serum soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients. Biol Psychiatry, 35(10), 767-71.
  162. Judd LL, Rapaport MH, Paulus MP, Brown JL (1994). Subsyndromal symptomatic depression: a new mood disorder? J Clin Psychiatry, 55 Suppl, 18-28.
  163. Rapaport MH, Stein MB (1994). Serum cytokine and soluble interleukin-2 receptors in patients with panic disorder. Anxiety, 1(1), 22-5.
  164. Rapaport MH, Stein MB (1994). Serum interleukin-2 and soluble interleukin-2 receptor levels in generalized social phobia. Anxiety, 1(2), 50-3.
  165. Rapaport MH, Wolkowitz O, Kelsoe JR, Pato C, Konicki PE, Pickar D (1993). Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients. Neuropsychopharmacology, 9(2), 111-5.
  166. Rapaport MH, Tipp JE, Schuckit MA (1993). A comparison of ICD-10 and DSM-III-R criteria for substance abuse and dependence. Am J Drug Alcohol Abuse, 19(2), 143-51.
  167. Rapaport MH, Torrey EF, McAllister CG, Nelson DL, Pickar D, Paul SM (1993). Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins. Eur Arch Psychiatry Clin Neurosci, 243(1), 7-10.
  168. Lauriello J, Kenny WM, Sutton L, Golshan S, Ruiz C, Kelsoe J, Rapaport M, Gillin JC (1993). The cholinergic REM sleep induction test with pilocarpine in mildly depressed patients and normal controls. Biol Psychiatry, 33(1), 33-9.
  169. Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH (1992). Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Arch Gen Psychiatry, 49(5), 345-53.
  170. Rapaport MH, McAllister CG, Kirch DG, Pickar D (1991). The effects of typical and atypical neuroleptics on mitogen-induced T lymphocyte responsiveness. Biol Psychiatry, 29(7), 715-7.
  171. Rapaport MH, Risch SC, Gillin JC, Golshan S, Janowsky D (1991). The effects of physostigmine infusion on patients with panic disorder. Biol Psychiatry, 29(7), 658-64.
  172. Lucas PB, Pickar D, Kelsoe J, Rapaport M, Pato C, Hommer D (1990). Effects of the acute administration of caffeine in patients with schizophrenia. Biol Psychiatry, 28(1), 35-40.
  173. McAllister CG, Rapaport MH, Pickar D, Podruchny TA, Christison G, Alphs LD, Paul SM (1989). Increased numbers of CD5+ B lymphocytes in schizophrenic patients. Arch Gen Psychiatry, 46(10), 890-4.
  174. Rapaport MH, Risch SC, Golshan S, Gillin JC (1989). Neuroendocrine effects of ovine corticotropin-releasing hormone in panic disorder patients. Biol Psychiatry, 26(4), 344-8.
  175. Rapaport MH, Risch SC, Gillin JC, Golshan S, Janowsky DS (1989). Blunted growth hormone response to peripheral infusion of human growth hormone-releasing factor in patients with panic disorder. Am J Psychiatry, 146(1), 92-5.
  176. Pato CN, Wolkowitz OM, Rapaport M, Schulz SC, Pickar D (1989). Benzodiazepine augmentation of neuroleptic treatment in patients with schizophrenia. Psychopharmacol Bull, 25(2), 263-6.
  177. Litman RE, Hommer DW, Clem T, Rapaport MH, Pato CN, Pickar D (1989). Smooth pursuit eye movements in schizophrenia: effects of neuroleptic treatment and caffeine. Psychopharmacol Bull, 25(3), 473-8.
  178. Risch SC, Golshan S, Rapaport MH, Dupont R, Outenreath R, Gillin JC, Janowsky DS (1988). Neuroendocrine effects of intravenous ovine corticotropin-releasing factor in affective disorder patients and normal controls. Biol Psychiatry, 23(7), 755-8.
  179. Breier A, Wolkowitz OM, Rapaport M, Paul SM, Pickar D (1988). Metabolic stress effects in normal volunteers and schizophrenic patients. Psychopharmacol Bull, 24(3), 431-3.
  180. Rapaport MH, Zisook S, Lyons LE (1988). Factors influencing outpatient attrition. Psychiatr Med, 6(4), 41-54.
  181. Cummings MA, Cummings KL, Rapaport MH, Atkinson JH, Grant I (1987). Acquired immunodeficiency syndrome presenting as schizophrenia. West J Med, 146(5), 615-8.
  182. Rapaport MH, Zisook S (1987). Requests by walk-in and scheduled patients at an outpatient clinic. Walk-in needs more varied and greater in number. Psychosomatics, 28(3), 129-32, 141-2.
  183. Levy GD, Rapaport MH (1985). Transderm scopolamine efficacy related to time of application prior to the onset of motion. Aviat Space Environ Med, 56(6), 591-3.

Editorial

  1. Bremner JD, Rapaport MH (2017). Vagus Nerve Stimulation: Back to the Future. Am J Psychiatry, 174(7), 609-610.
  2. Rapaport MH (2017). Introducing a New Section: The Applied Armamentarium. Focus (Am Psychiatr Publ), 15(1), 3.
  3. Dunlop BW, Rakofsky JJ, Rapaport MH (2013). A simple question answered: adding moderate-dosage lithium does not help patients with bipolar disorder. Am J Psychiatry, 170(1), 9-11.
  4. Freedman R, Lewis DA, Michels R, Pine DS, Schultz SK, Tamminga C, Patterson SL, McIntyre JS, Goldman HH, Yudofsky SC, Hales RE, Rapaport MH, Hales D, Krajeski J, Kupfer DJ, Badaracco MA, Scully JH Jr (2006). Conflict of interest, round 2. Am J Psychiatry, 163(9), 1481-3.

Letter

  1. Targum SD, Little JA, Lopez E, Demartinis N, Rapaport M, Ereshefsky L (2012). Application of external review for subject selection in a schizophrenia trial. [Letter to the editor]. J Clin Psychopharmacol, 32(2), 825-6.
  2. Mendlowicz MV, Rapaport MH, Fontenelle L, Jean-Louis G, De Moraes TM (2002). Amnesia and neonaticide. [Letter to the editor]. Am J Psychiatry, 159(3), 498-9.
  3. Mendlowicz MV, da Silva Filho JF, Gekker M, de Moraes TM, Rapaport MH, Jean-Louis F (2000). Mothers murdering their newborns in the hospital. [Letter to the editor]. Gen Hosp Psychiatry, 22(1), 53-5.
  4. Dolnak D, Rapaport MH, Hawthorne W (1998). Residential treatment for patients in crisis. [Letter to the editor]. Psychiatr Serv, 49(2), 246.
  5. Rapaport MH (1997). Clinical differences between the generic and nongeneric forms of clonazepam. [Letter to the editor]. J Clin Psychopharmacol, 17(5), 424.
  6. Alonso M, Val E, Rapaport MH (1997). An open-label study of SSRI treatment in depressed hispanic and non-Hispanic women. [Letter to the editor]. J Clin Psychiatry, 58(1), 31.
  7. Rapaport MH (1994). Missed psychiatric appointments. [Letter to the editor]. Am J Psychiatry, 151(5), 786.
  8. Rapaport MH (1994). Carbon-dioxide-induced panic. [Letter to the editor]. Am J Psychiatry, 151(2), 292.
  9. Challakere K, Rapaport MH (1993). False-positive human immunodeficiency virus type I ELISA results in low-risk subjects. [Letter to the editor]. West J Med, 159(2), 214-5.
  10. Rapaport MH, Doran AR, Nelson DL, McAllister C, Magliozzi JR, Paul SM (1991). Haloperidol and soluble interleukin-2 receptors. [Letter to the editor]. Biol Psychiatry, 30(10), 1063-4.
  11. Regier DA, Shore D, Rapaport MH, Prien R, Keith SJ (1991). NIMH bulletins and redundant publication. [Letter to the editor]. Biol Psychiatry, 29(3), 307-8.
  12. McAllister CG, Rapaport MH, Pickar D, Paul SM (1989). Effects of short-term administration of antipsychotic drugs on lymphocyte subsets in schizophrenic patients. [Letter to the editor]. Arch Gen Psychiatry, 46(10), 956-7.
  13. Rapaport MH, McAllister CG, Pickar D, Nelson DL, Paul SM (1989). Elevated levels of soluble interleukin 2 receptors in schizophrenia. [Letter to the editor]. Arch Gen Psychiatry, 46(3), 291-2.
  14. Rapaport MH, Cummings MA, Cummings KL, Risch SC (1987). Research diagnostic problems. [Letter to the editor]. Am J Psychiatry, 144(6), 826-7.
  15. Rapaport MH (1987). Chronic pain and posttraumatic stress disorder. [Letter to the editor]. Am J Psychiatry, 144(1), 120.
  16. Cummings MA, Rapaport M, Cummings KL (1986). A psychiatric staff response to acquired immune deficiency syndrome. [Letter to the editor]. Am J Psychiatry, 143(5), 682.
  17. Rapaport M, Braff DL (1985). Alprazolam and hostility. [Letter to the editor]. Am J Psychiatry, 142(1), 146.

Other

  1. Rapaport MH (2009). ECP news. The new investigator program at the NCDEU meeting: opportunities found for all. J Clin Psychiatry (70(1), p. 130). United States.